Summary A phase II trial investigating the anti-tumour effects of recombinant human interleukin 6 (rhIL-6) in patients with metastatic renal cell cancer was carried out. g) 
Metastatic renal cell carcinoma has a poor prognosis for most patients, with a median survival of less than 1 year (Marston et al., 1989) . Efforts to improve this survival by chemotherapeutic agents have been largely unsuccessful (Yagoda et al., 1993) . Recently, immunotherapy has received much attention (Wirth, 1993) . Although a moderate effectiveness of both IL-2 and interferon-a has been observed, long-term disease-free survival after treatment with cytokines has not been documented in a randomised fashion (Wirth, 1993) . Therefore, the need for new effective and safe therapies remains.
Interleukin 6 (IL-6) is a multifunctional cytokine (Le and Vilcek, 1989 ) that has stimulatory effects on thrombocytopoiesis (Ishibashi and Asano, 1992) , B-and T-cell differentiation (Kishimoto and Hirano, 1988; Houssiau and Van Snick, 1992) and the hepatic acute phase response (Gauldie et al., 1992) , as well as a mediatory role in the metabolic and endocrinological response to inflammation (Stouthard et al., 1994 (Stouthard et al., , 1995 . Furthermore, experimental and preclinical data indicate that IL-6 may have direct and indirect anti-tumour activity in solid tumours (Revel, 1992; Chen et al., 1988; Mule et al., 1990 Mule et al., , 1992 .
Here, we describe our results of a multicentre phase II trial of recombinant human (rh)IL-6 in patients with metastatic renal cell cancer. This study was initiated after the observation of a complete remission of pulmonary metastases in a patient with renal cell carcinoma after a 6 week course of daily subcutaneous recombinant human IL-6 (rhIL-6) injections as an experimental drug for thrombocytopenia (A Gianella-Borradori, personal communication) . Using the same treatment schedule, we investigated anti-tumour effects, toxicity, haematological and biochemical changes and the induction of anti-IL-6 antibodies in patients with metastatic renal cell cancer, both with and without previous immunotherapy. Patients Neutralising antibodies to rhIL-6 were detected using a IL-6 growth-dependent cell line (B13.29), with neutralising antiserum obtained from a goat as a positive control. A serum sample was considered as positive for neutralising antibodies if it inhibited the proliferative response to 5 units ml-' rhIL-6, and if the percentage inhibition was at least twice the percentage inhibition of the pretreatment serum sample at the equivalent dilution.
Response criteria Only patients who completed the 6 week treatment period were included in the evaluation. A complete response was defined as the total disappearance of all detectable malignant disease for at least 4 weeks. A partial response was defined as a >50% reduction of (the sum of) the product(s) of the longest diameter and the greatest perpendicular diameter of a given lesion(s) (diameter product), and no appearance of new lesions for at least 4 weeks. A minor response was defined as a reduction of >25% but <50% by the same definitions. 
Results

Patient characteristics
The demographic and disease characteristics of the patients are given in Table I . A total of 49 patients was included; 12 patients with, and 37 patients without previous immunotherapy. There were no significant differences between the two groups. Of the previously treated patients, five received IL-2, four IL-2 + a-interferon (a-IFN) + lymphokine-activated killer cells, and three received oc-IFN. The median interval until start of the IL-6 treatment was 8 (range 3-32) months. Two patients had a partial remission, whereas none of the others responded.
Tumour responses
The responses to rhIL-6 treatment are given in Table II. In the group that had had previous immunotherapy, 10 out of 12 patients were evaluable for response. There were no minor, partial or complete responses observed. Stable disease was noted in five patients. Of the five patients who had stable year-old male with pulmonary and liver metastases that progressed on chemotherapy with fluorodeoxyuridine, administered until 2 months before rhIL-6 treatment. A radical nephrectomy had been performed 36 months before. The patient noticed a considerable improvement in well-being while on rhIL-6 treatment. At the end of the 6 week rhIL-6 treatment course an approximately 60% tumour reduction was noted, with a further reduction during the next 10 weeks (total tumour reduction 80%). A second 6 week rhIL-6 treatment, initiated 4 months later because of recurrent disease, unfortunately failed to reinduce a remission. The other partial response was observed in a 65-year-old male who underwent a radical nephrectomy 36 months before, and who had para-aortic lymph node metastases that were progressive at study entry. After 6 weeks of rhIL-6 treatment stable disease was noted. Three months later, without any subsequent treatment, a partial remission was found on the basis of a 55% reduction in diameter product, that lasted 2 months. Of the other 35 patients in this group, 28 were evaluable for tumour response; 12 had stable disease, 16 had progressive disease. There were no minor responses. Seven of the 11 patients who had stable disease at entry, remained stable. Of the 15 patients who had progressive disease at the start of the rhIL-6 treatment, one had a partial response (see above) and four were stable throughout the treatment period. Toxicity Side-effects are summarised in Table III. All patients were evaluable for toxicity, and since there were no differences in side-effects between patients with or without previous immunotherapy, the data of group I and II were pooled.
The main side-effects were fever (89% of the patients), favourably responding to acetaminophen in most patients; flu-like symptoms such as fatigue (22%), headache (14%) and myalgia or arthralgia (12%); nausea (37%); weight loss (37%); and hepatotoxicity, as indicated by increases in AF Diarrhoea 2 --791 (63%) and y-GT (61%). Two patients developed hypercalcaemia during rhIL-6 treatment. One patient had rapid progression of this disease. The other patient had stable disease. After institution of biphosphonate therapy his plasma calcium levels normalised. Finally, all patients had local erythema at the injection site, which subsided within 48 h. All toxicity reversed within 4 weeks after discontinuation of the rhIL-6 treatment. Nine patients had to discontinue rhIL-6 treatment prematurely, i.e. after a mean of 31 weeks: two patients in group I and seven in group II.
The reasons for discontinuing rhIL-6 treatment were fatigue, leading to semi permanent bedrest, in two patients, accompanied by severe mental depression in one; deterioration of their general condition due to tumour progression in three patients; gross haematuria due to haemorrhage from the primary tumour in the kidney, with subsequent urosepsis, in one patient; hemiparesis due to tumour progression, for which radiation therapy had to be instituted, in one patient; fatal cerebral haemorrhage, without evidence of central nervous system metastases on CT scanning, but with a history of hypertension, in one patient; lack of ability to comply with the protocol in one patient.
Haematology and acute phase response Figures 1 and 2 show the time course of the haematological effects of and the acute phase response to rhIL-6 treatment. Anaemia was a frequently noted side-effect, necessitating blood transfusions in 13 patients. Haemoglobin content progressively declined during the rhIL-6 administration by a mean of approximately 19% (from 8.5 +0.2 to 6.5+0.1 mmol 1-1, baseline vs nadir P<0.001). At week 10, Administration of rhIL-6 led to a significant increase in leucocyte count (from 7.3 + 0.3 x 109 I`at baseline to 8.6+0.4x109 1 -at week 3, P<0.001) (Figure 1 ), without major changes in differential counts. A gradual increase of the thrombocyte count, reaching a plateau after 3 weeks (from 298+15 to 456+17x1091-; baseline vs week 3, P<0.001) was observed (Figure 1 ). At week 10 the thrombocyte count was not different from baseline. RhIL-6 also induced an acute phase response, as indicated by increases in CRP (from 28+5 mg 1-' at baseline to 149+7 mg l-' at week 2, P<0.001) and fibrinogen (from 5.58+0.26 mg l-' to 8.76+0.36 mg l-l at week 2, P<0.001) (Figure 2 ). ESR increased parallel to the increases in fibrinogen (from 47+5mmh -to 105+3mmh at week 2, P<0.001). At week 10 CRP and fibrinogen concentration, but not ESR, had returned to baseline values.
IL-6 concentrations and immunogenecity Pretreatment samples for determination of IL-6 concentrations and pre-and post-treatment samples for determination of anti-IL-6 antibodies were received from 41 subjects. At baseline the IL-6 concentrations were below the detection limit in 17 subjects. Figure 3 shows the individual baseline IL-6 concentrations of the patients whose tumour status at entry was known. Furthermore, baseline IL-6 concentrations in relation to tumour response are given. From these data it can be concluded that there was no statistically significant difference in IL-6 concentrations between those who had stable or progressive disease at entry, or between those who did or did not respond to rhIL-6 treatment.
Anti-IL-6 antibodies were detected in five patients in group I and in 1 patient in group II. On quantitative analysis, the anti-IL-6 antibody titres varied from 1:100 to 1:300. Of these patients, three had stable disease after rhIL-6 treatment, and three had progressive disease. Neutralising antibodies were only detectable in the one patient with anti-IL-6 antibodies in group II. This patient had pulmonary metastases that were stable at study entry, and his disease progressed during rhIL-6 treatment.
Discussion
This phase II trial investigated the anti-tumour effects of interleukin 6 in metastatic renal cell cancer. Two partial remissions were noted. Spontaneous tumour regression in metastatic renal cell carcinoma, especially shortly after surgical removal of the primary tumour, has been observed in less than 1% of all patients (Marston et al., 1989) . However, since neither of these two patients underwent a recent nephrectomy, the inhibition of tumour growth may have been the consequence of the rhIL-6 administration. Antitumour effects of IL-6 in experimental studies may be either direct (Chen et al., 1988) or mediated by enhancing cytotoxic T-lymphocytes (Mule et al., 1992; Porgador et al., 1992) or by other as yet undefined routes. A non-direct anti-tumour effect in our patients seems more likely, given the perpetuation of tumour reduction after completion of the rhIL-6 treatment. This latency is in accordance with previous findings in patients with renal cell cancer who responded to other immunotherapy (Wirth, 1993 Anti-IL-6 antibodies during or after rhIL-6 treatment were detected in 15% ofthe patients. Halfof these patients had stable disease after rhIL-6 treatment, the other halfprogressive disease. Neutralising antibodies were detected in only one patient. It is therefore concluded that our results were not affected by the interference of antibodies against the rhIL-6 used.
This study was initiated after observing a tumour response of pulmonary metastases in a patient with renal cell carcinoma after rhIL-6 treatment. The role of IL-6 in renal cell carcinoma, however, is complex. Paraneoplastic symptoms, such as cachexia, fever, elevated erythrocyte sedimentation rate and anaemia, commonly observed in renal cell cancer (Wirth, 1993) , have been linked to the presence of elevated plasma concentrations of IL-6 in these patients (Blay et al., 1992; Tsukamoto et al., 1992) . As a source of IL-6 the renal carcinoma itself could be appointed, since both normal (Gogusev et al., 1993) and malignant renal cells (Tsukamoto et al., 1992; Gogusev et al., 1993) have been shown to produce and release IL-6. Moreover, in vitro data indicate that IL-6 may act as an autocrine growth factor in these tumours (Miki et al., 1989; Gruss et al., 1991; Koo et al., 1992) . On the other hand, IL-6 is not an independent predictor of survival as would be predicted if it were a clinically important autocrine growth factor (Stadler et al., 1992) . In our patient population neither endogenous baseline IL-6 concentrations nor the exogenous IL-6 administration could be related to tumour behaviour.
In two previous, preliminary reports a 5-day continuous infusion of a 15-fold higher dosage of rhIL-6 (n= 12), or a 14 day course of s.c. rhIL-6 administration (n =1) in patients with metastatic renal cell cancer resulted in no objective responses (Ravoet et al., 1994; Weiss et al., 1994) . We observed a partial remission in only 2 out of 49 (4%) patients. The patient characteristics of the responders in our study were not discernible from those of the non-responders. Therefore, at present rhIL-6 given as a daily s.c. injection for 6 weeks cannot be advocated as a treatment modality for metastatic renal cell carcinoma. Our data further indicate, however, that prolonged treatment with rhIL-6 can be performed safely on an outpatient basis and is associated with moderate, reversible toxicity. Finally, continuous rhIL-6 administration is accompanied by the development of nonneutralising anti-IL-6 antibodies in only a minority of patients.
